Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs standard-dose chemotherapy plus tislelizumab as neoadjuvant therapy for esophageal squamous cell carcinoma
ChiCTR2500108447Phase 3Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tislelizumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: pathological complete response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tislelizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500108447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108447.